- Report
- October 2023
- 176 Pages
Global
From €4105EUR$4,500USD£3,531GBP
- Report
- April 2025
- 185 Pages
Global
From €4105EUR$4,500USD£3,531GBP
- Report
- October 2023
- 181 Pages
Global
From €4105EUR$4,500USD£3,531GBP
- Report
- August 2022
- 109 Pages
Global
From €4333EUR$4,750USD£3,727GBP
- Report
- January 2024
- 116 Pages
Global
From €3500EUR$4,110USD£3,115GBP
- Report
- August 2023
- 104 Pages
Global
From €3500EUR$4,110USD£3,115GBP
- Report
- May 2023
- 90 Pages
Global
From €3500EUR$4,110USD£3,115GBP
- Report
- September 2022
- 104 Pages
Global
From €1825EUR$2,000USD£1,569GBP
Voriconazole is an antifungal medication used to treat a variety of fungal infections, including those caused by Aspergillus and Candida species. It is a member of the triazole class of antifungal drugs, and is commonly used in the treatment of serious fungal infections in immunocompromised patients. Voriconazole is also used to treat infections caused by other fungi, such as Fusarium and Scedosporium species.
Voriconazole is available in both oral and intravenous formulations, and is generally well tolerated. Common side effects include visual disturbances, rash, and nausea. It is important to note that voriconazole can interact with other medications, and should be used with caution in patients with liver or kidney disease.
Voriconazole is a key player in the infectious diseases drugs market, and is used to treat a variety of fungal infections. It is an important treatment option for immunocompromised patients, and is generally well tolerated.
Some companies in the voriconazole market include Pfizer, Novartis, Merck, and Astellas Pharma. Show Less Read more